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Abstract 
Background: Chronic kidney disease (CKD) leads to end‑stage renal failure and cardiovascular events. An attribute 
to these progressions is abnormalities in inflammation, which can be evaluated using the neutrophil‑to‑lymphocyte 
ratio (NLR). We aimed to investigate the association of NLR with the progression of end stage of renal disease (ESRD), 
cardiovascular disease (CVD) and all‑cause mortality in Chinese patients with stages 1–4 CKD.
Methods: Patients with stages 1–4 CKD (18–74 years of age) were recruited at 39 centers in 28 cities across 22 
provinces in China since 2011. A total of 938 patients with complete NLR and other relevant clinical variables were 
included in the current analysis. Cox regression analysis was used to estimate the association between NLR and the 
outcomes including ESRD, CVD events or all‑cause mortality.
Results: Baseline NLR was related to age, hypertension, serum triglycerides, total serum cholesterol, CVD history, 
urine albumin to creatinine ratio (ACR), chronic kidney disease‑mineral and bone disorder (CKD‑MBD), hyperlipidemia 
rate, diabetes, and estimated glomerular filtration rate (eGFR). The study duration was 4.55 years (IQR 3.52–5.28). Cox 
regression analysis revealed an association of NLR and the risk of ESRD only in patients with stage 4 CKD. We did not 
observe any significant associations between abnormal NLR and the risk of either CVD or all‑cause mortality in CKD 
patients in general and CKD patients grouped according to the disease stages in particular.
Conclusion: Our results suggest that NLR is associated with the risk of ESRD in Chinese patients with stage 4 CKD. 
NLR can be used in risk assessment for ESRD among patients with advanced CKD; this application is appealing consid‑
ering NLR being a routine test.
Trial registration ClinicalTrials.gov Identifier NCT03041987. Registered January 1, 2012. (retrospectively registered) 
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Background
Chronic kidney disease (CKD) is a growing health prob-
lem with an estimated prevalence of 10.8–16% in major 
developed and developing countries [1, 2]. Individuals 
with CKD are at risk of progressive kidney failure, cardio-
vascular events, and death [3, 4].
Nonmicrobial inflammation contributes to CKD pro-
gression and fibrosis [5]. The neutrophil count reflects 
inflammation, while the lymphocyte count indicates the 
status of general stress and nutrition. The neutrophil-
to-lymphocyte ratio (NLR) in CKD patients provides 
information on the inflammation status [6]. It is sug-
gested that NLR is a complementary prognostic marker 
for evaluating the cardiovascular risk in CKD3-5 patients 
[6]. Studies demonstrated that an increase in neutrophil 
count coupled with a reduction in lymphocyte counts 
predicts mortality in hemodialysis patients [7] and peri-
toneal dialysis patient [8]. Also, NLR indicates the rate of 
stage 4 chronic kidney disease progressing to dialysis [9]. 
Nevertheless, studies of NLR for its prognosis potential 
towards ESRD, CVD and all-cause mortality in patients 
with stage 1–4 CKD other than stage 5 CKD are rare. 
Since NLR is readily derived from complete blood count 
tests, its potential as a predictor should be investigated in 
a large cohort of patients with stage 1–4 CKD.
The objective of this study was to evaluate whether 
NLR, a simple marker of chronic systemic inflamma-
tion, predicts the progression of ESRD, CVD and all-
cause mortality among CKD1–4 patients in the Chinese 
Cohort Study of Chronic Kidney Disease (C-STRIDE), 
the first national prospective CKD cohort of the Chinese 
population.
Materials and methods
The design, methods, and baseline characteristics of 
the Chinese Cohort Study of Chronic Kidney Disease 
(C-STRIDE) study population has been published; this 
is a prospective investigation involving 39 clinical cent-
ers in 28 cities of 22 provinces in China [10]. The design 
of C-STRIDE has been described in detail elsewhere [11]. 
A total of 3358 participants were included until Decem-
ber 31, 2017 after exclusion of patients with missing 
value of key demographic variables (including blood rou-
tine and blood lipid) or loss of follow-up. Of these 3358 
participants, 938 patients have NLR and other relevant 
clinical variables and were used in the current analysis. 
The C-STRIDE study was approved by the ethics com-
mittee of Peking University First Hospital and was in 
adherence with the Declaration of Helsinki. All partici-
pants have consented this study. During the study visit, 
all C-STRIDE study data were collected by trained staff 
according to the study protocol [12]. Data were obtained 
by questionnaires, anthropometric measurements, col-
lection of blood and urine specimens. The albumin/cre-
atinine ratio (ACR) stage was categorized according to 
an analysis of a spot urine sample: A1 (normoalbuminu-
ria), ACR < 30  mg/g creatinine; A2 (microalbuminuria), 
30 ≤ ACR < 300  mg/g creatinine; or A3 (macroalbumi-
nuria), ACR ≥ 300  mg/g creatinine. GFR was estimated 
from serum creatinine measurements and demographic 
characteristics by the Chronic Kidney Disease Epide-
miology Collaboration (CKD-EPI) equation [1, 13]. 
Smoking was defined as currently smoking or had ever 
smoked. Alcohol consumption was defined as a habitual 
drinker (drink once a day or more). Hypertension was 
defined as a systolic blood pressure (BP) ≥ 140  mmHg 
and/or a diastolic BP ≥ 90  mmHg, or a self-reported 
history of hypertension. Levels of hemoglobin, NLR, 
fasting blood glucose, serum triglycerides, total cho-
lesterol, LDL-cholesterol, HDL cholesterol, uric acid, 
serum phosphate, serum calcium, hs-CRP, iPTH, HbA1c, 
were documented. Plain lateral abdominal x-ray film 
showed abdominal aortic calcification. CKD-MBD was 
defined as a triad of interrelated abnormalities of serum 
biochemistry (serum phosphate levels > 1.49  mmol/L 
or < 0.87  mmol/L; serum calcium levels > 2.57  mmol/L 
or < 2.1 mmol/L, and iPTH > 70 pg/mL or < 35 pg/mL); or 
calcification of lateral abdominal x-ray film. Patients were 
considered to have diabetes mellitus if they had a fasting 
glucose ≥ 7.0 mmol/L; an HbA1c ≥ 6.5%; took insulin or 
other anti-diabetic medications; or reported a history of 
diabetes. CVD history was defined as the past occurrence 
of a myocardial infarction, admittance into a hospital for 
congestive heart failure, or severe cardiac arrhythmia 
incidents (resuscitated cardiac arrest, ventricular fibrilla-
tion, sustained ventricular tachycardia, paroxysmal ven-
tricular tachycardia, atrial fibrillation or flutter, severe 
bradycardia, or heart block). Hyperlipidemia was defined 
as total cholesterol level ≥ 5.7  mmol/L or an LDL-cho-
lesterol level ≥ 3.6  mmol/L. Hyperuricemia was defined 
as a serum concentration of uric acid ≥ 420  μmol/L for 
men and ≥ 360  μmol/L for women. The abnormal of 
hsCRP was ≥ 3 mg/dL [14]. The kidney disease outcomes 
evaluated in this paper are three facets: (1) ESRD that 
was defined as progression to hemodialysis, peritoneal 
dialysis or renal transplantation; (2) CVD risk that was 
evaluated based on onset of CVD events (myocardial 
infarction, heart failure, arrhythmia and cerebrovascular 
disease and peripheral arterial disease) and (3) all-cause 
mortality (deaths). Doctors at the clinical centers were 
requested to submit related clinical data to Renal Insti-
tute of Peking University. All events were adjudicated by 
an independent committee consisting of specialists.
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Statistical analyses
Demographic information and other baseline variables 
were described using mean ± SD or median and inter-
quartile range for continuous variables and frequency 
and proportion for categorical variables. Chi-square or 
Fisher’s exact test was used for comparison of categori-
cal variables between groups, while Mann–Whitney U 
test or unpaired Student’s t test was used for continuous 
variables. We identified the cutoff point for NLR level 
using maximally selected log-rank statistics. Prevalence 
of events according to NLR categorical variables and 
estimate survival time for each category are calculated 
with Kaplan–Meier Survival and time-to-event analy-
sis of outcomes were performed using Cox proportional 
hazards model, including adjustment for potential con-
founding factors. Covariates for the models were selected 
based on prior knowledge about the factors that could be 
potential confounders of the associations of NLR with 
ESRD. The potential confounders including age (con-
tinuous), gender (male vs. female), smoking (yes vs. no), 
drinking more than once a day (yes vs. no), clinical char-
acteristics [hypertension (yes vs. no), CKD-MBD (yes vs. 
no), diabetes (yes vs. no), CVD (yes vs. no), hyperlipidae-
mia (yes vs. no), hyperuricemia (yes vs. no)], hemoglobin 
(continuous), eGFR (continuous), ACR categories (A1, 
A2, A3). A p value  <  0.05 was regarded as statistically 
significant. Proportional hazards assumptions were veri-
fied by testing the interaction with time using the likeli-
hood ratio test, which yielded non-significant p values. 
The results are presented as hazard ratios (HRs) with 95% 
confidence intervals (CIs). p values for trend were given 
by treating dichotomy NLR as a continuous variable. We 
hypothesized that the effect of NLR might be modified 
by the CKD stage. The interaction terms were generated 
between NLR and each of the eGFR levels (CKD1-2 vs. 
all others, CKD3 vs. all others, CKD4 vs. all others). A 
stratified analysis in the prediction of ESRD events was 
conducted by the stages of CKD. A series of sequential 
models were fit to evaluate the effect of adding certain 
sets of covariates. All statistical analyses were performed 




Among the total 938 CKD patients from C-STRIDE, the 
median follow-up time for the adverse outcomes was 
4.55 (IQR 3.52–5.28) years. Baseline characteristics of the 
study population are described in Table 1. The mean age 
of the study population was 52.8  years; 58% of patients 
were male. 34.2% of patients were reported ever smok-
ing and 21% of patients were documented drinking ≥ 1 
times per day. At the baseline, 360 (38.4%) patients had 
an eGFR greater than 60 mL/min 1.73 m−2; 345 (36.8%), 
and 233 (24.8%) patients were in CKD stage 3 and 4, 
respectively. Baseline demographics and biochemical 
measurements of CKD patients according to dichotomy 
of baseline NLR are summarized in Table 1. Higher base-
line NLR levels were associated with older age, higher 
blood pressure, hyperlipidaemia, CVD, CKD-MBD, dia-
betes, but lower levels of eGFR. The cutoff point for the 
serum NLR level for renal replacement progression was 
2.09 (Fig.  1). We also compare the baseline characteris-
tics of 2420 patients without record of NLR in 3359 par-
ticipants to those who has the record of NLR (Additional 
file  1: Table  S1). There are differences in ever smoking, 
BMI category, hypertension, uric acid, serum triglycer-
ides, hyperuricemia, LDL cholesterol, HDL cholesterol, 
hyperlipidaemia, serum phosphorus (sP),  HCO3− and 
eGFR between NLR group and non-NLR group, but there 
are no difference in age, sex, drinking, HGB, total serum 
cholesterol, cardiovascular disease (CVD), ACR, serum 
calcium (sCa) and diabetes.
The incidence rates of ESRD other than CVD and all‑cause 
mortality events were associated with NLR
The incidence rates of ESRD, CVD and all-cause mortal-
ity events according to binary of NLR levels are shown in 
Table 2. During the median follow-up of 4.55 (IQR 3.52–
5.28) years, there were 123 ESRD events occurred. ESRD 
rates were 3.14 per 100 person-years. Higher incidence 
rate of ESRD events was observed with increases in NLR 
(Fig.  2, p for log-rank test < 0.001). There were 57 CVD 
and 43 all-cause mortality events; the occurance of both 
events was not associated with NLR levels (Table 2). Fur-
thermore, we did not detect any significant correlations 
among hsCRP, another marker of inflammation, with all-
cause mortality rates, ESRD rates and CVD events (Addi-
tional file 1: Table S2).
Associations between NLR and ESRD
The associations between NLR and ESRD are shown 
in  Table  3. After adjustment for demographic and tra-
ditional ESRD risk factors, as well as the baseline eGFR 
categories and ACR, baseline NLR was independently 
associated with the occurrence of ESRD in CKD stage 4 
patients, with an HR value 2.12 (95% CI 1.10–4.10) com-
pared with the lower NLR (p = 0.025).
Discussion
The current study suggests that baseline NLR is asso-
ciated with an increased risk of ESRD in pre-dialysis 
patients with stage 4 CKD; the association was independ-
ent of traditional risk factors of CKD including ACR and 
eGFR.
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In CKD patients, declines in glomerular filtration rate 
are associated with increases in the risk of CVD and 
rapid progression of CKD to end-stage renal disease 
and mortality [15, 16]. CKD is a chronic inflammatory 
condition and remains a substantial economic burden 
on the patient, caregiver and society [17]. Inflamma-
tion is one of the most important initiators of progres-
sive tubule-interstitial fibrosis, which usually culminates 
in ESRD [18]. Several studies have reported that inflam-
mation plays a role in the decline of kidney function [19]. 
Table 1 Baseline demographic characteristics of participants of C-STRIDE Study according to NLR
The number of missing values for each variable: NLR 0, age 0, eGFR 0, sex 0, education 31, ever smoking 51, drinking ≥ 1 times per day 60, BMI category 211, anemia 
0, systolic blood pressure 186, diatolic blood pressure 186, antihypertensive medications token in 2 weeks 334, uric acid 30, total serum cholesterol 338, serum 
triglycerides 347, LDL cholesterol 428, HDL cholesterol 425, CKD-MBD 0, cardiovascular disease 28, ACR 149, metabolic acidosis 589, pathogenesis chronic 0, high 
Hs-CRP 668
The denominator of percentage is number of the variable
* The variable is numerical and statistics is mean (standard deviation), p-value calculated based on T test
# The variable is numerical and statistics is Median (Interquartile range), p-value calculated based on Wilcoxon test
$ The variable is character and statistics is frequency (percentage), p-value calculated based on Chi-square test
** Statistically significant at 0.05
Variable Total (n = 938) NLR ≥ 2.09 (n = 520) NLR < 2.09 (n = 418) p value
Age (year)* 52.8 (14.14) 54.0 (14.48) 51.3 (13.58) 0.047**
Sex (men)$ 544 (58.00%) 304 (58.46%) 240 (57.42%) 0.747
Ever  smoking$ 311 (34.2%) 180 (35.7%) 131 (32.3%) 0.276
Drinking ≥ 1 times per  day$ 189 (21.00%) 101 (20.2%) 88 (22.0%) 0.510
BMI category (kg/m2)# 24.61 (22.04–27.34) 24.61 (22.01–27.42) 24.59 (21.99–27.31) 0.944
HGB (g/L)* 129.2 (22.78) 125.7 (23.00) 133.70 (21.71) 0.183
Systolic blood pressure (mmHg)* 127.51 (16.71) 129.91 (17.88) 124.92 (14.96) 0.537
Diastolic blood pressure (mmHg)* 80.13 (10.48) 81.11 (11.01) 79.08 (9.78) 0.918
Antihypertensive medications token in 
2 weeks$
507 (69.5%) 288 (74.0%) 219 (64.4%) 0.005**
Hypertension$ 538 (57.4%) 303 (58.3%) 235 (56.2%) < 0.001**
Uric acid (μmol/L)* 373.59 (132.08) 376.59 (136.42) 369.87 (126.55) 0.208
Serum triglycerides (mmol/L)# 1.66 (1.18–2.39) 1.61 (1.13–2.26) 1.79 (1.21–2.59) 0.021**
Hyperuricemia$ 407 (44.3%) 235 (46.2%) 172 (42.0%) 0.201
Total serum cholesterol (mmol/L)# 4.70 (4.01–5.57) 4.59 (3.94–5.39) 4.82 (4.12–5.89) 0.003**
LDL cholesterol (mmol/L)# 2.73 (2.22–3.40) 2.72 (2.20–3.36) 2.74 (2.23–3.48) 0.369
HDL cholesterol (mmol/L)# 1.12 (0.91–1.34) 1.12 (0.93–1.34) 1.12 (0.89–1.34) 0.729
Hyperlipidaemia$ 194 (26.6%) 98 (23.7%) 96 (30.5%) 0.039**
Cardiovascular  disease$ 124 (13.40%) 81 (15.80%) 43 (10.40%) 0.017**
ACR (mg/g creatinine)# 343.05 (75.60–780.51) 420.50 (112.11–312.90) 290.01 (48.20–666.86) 0.000**
ACR  group$ 814 447 367 0.006**
 1 < 30 mg/g 127 (15.6%) 56 (12.5%) 71 (19.3%)
 2 = 30–299 mg/g 248 (30.5%) 130 (29.1%) 118 (32.2%)
 3 ≥ 300 mg/g 439 (53.9%) 261 (58.4%) 178 (48.5%)
sCa (mmol/L)* 2.22 (0.18) 2.23 (0.18) 2.22 (0.18) 0.735
sP (mmol/L)# 1.17 (1.05–1.31) 1.17 (1.04–1.31) 1.18 (1.05–1.32) 0.925
CKD‑MBD$ 467 (54.6%) 274 (58.1%) 193 (50.3%) 0.023**
HCO3− (mmol/L)* 25.70 (3.78) 25.54 (3.99) 25.91 (3.49) 0.060
Diabetes$ 200 (23.8%) 135 (29.4%) 65 (17.1%) 0.000**
eGFR (mL/min/1.7  m2)* 57.22 (32.67) 48.73 (29.63) 67.78 (33.24) 0.000**
eGFR  group$ 938
 ≥ 60 mL/min/1.73 m2 360 (38.4%) 139 (26.7%) 221 (52.9%) 0.000**
 30–60 mL/min/1.73 m2 345 (36.8%) 212 (40.8%) 133 (31.8%)
 15–30 mL/min/1.73 m2 233 (24.8%) 169 (32.5%) 64 (15.3%)
High hs‑CRP 146 (15.6%) 88 (16.9%) 58 (13.9%) 0.414
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Anti-inflammatory treatment in tubulointerstitial fibro-
sis of CKD may have renal protective effects [20–23]. An 
alternative marker of systemic inflammation, c-reactive 
protein (CRP) has been shown to be a superior prognos-
tic marker if it is persistently elevated [24, 25]. HsCRP 
was found to be a predictor of mortality and ESRD in 
pre-dialysis patients with chronic kidney disease [26]. 
HsCRP, which is synthesized mainly in the  liver, only 
marginally increased even in patients with active infec-
tion [24]. Furthermore, it is non-specific and may not 
fully capture all forms of inflammation [27]. For example, 
the Multi-Ethnic Study of Atherosclerosis (MESA) dem-
onstrated obesity being independently associated with 
subclinical atherosclerosis irrespective of hsCRP, with 
no additive effect when elevated hsCRP was present [28]. 
What is more, hsCRP is influenced by other factors such 
as body mass index, weight loss, smoking, active alcohol 
consumption and diabetes [29]. Similar in our study, we 
observed that hsCRP was not correlated with the out-
come in CKD stage 1–4 patients. hsCRP is thus likely not 
a good inflammation indicator in CKD patients; other 
inflammation biomarkers should be investigated to strat-
ify patients with stage 1–4 CKD who are at risk of poor 
prognosis and to monitor treatment effects.
Studies with relatively small-scale have recently been 
conducted on whether NLR may be a predictor of CKD 
progression. The balance between the inflammatory and 
immune response is also reflected by NLR [7], which 
shows chronic low-grade inflammation. In addition to a 
variety of well-known risk factors for CKD progression, 
this study was aimed to evaluate the relationship between 
NLR and CKD progression. We used NLR as a surrogate 
marker of systemic inflammation. NLR is composed of 
two different complementary immune pathways [30], 
Fig. 1 Maximally selected log‑rank statistics for cutoff point of NLR
Table 2 Relationship between  NLR levels and  ESRD, CVD 
and all-cause mortality events rates







 < 2.09 (N = 418) 31 (7.4%) 1.76 < 0.001
 ≥ 2.09 (N = 520) 92 (17.7%) 4.27
 Total 123 (17.02%) 3.14
CVD events
 < 2.09 (N = 418) 19 (4.5%) 1.03 0.081
 ≥ 2.09 (N = 520) 38 (7.3%) 1.69
 Total 57 (6.1%) 1.39
All‑cause mortality events
 < 2.09 (N = 418) 14 (3.4%) 0.75 0.118
 ≥ 2.09 (N = 520) 29 (5.5%) 1.26
 Total 43 (4.6%) 1.03
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and is less likely to be influenced by various physiological 
conditions such as dehydration. Because some inflamma-
tory cytokines, such as hsCRP, interleukin-6 and TNF-α 
are limited to research for nonconventional tests, NLR 
would be more easily available for clinical practice [31]. 
NLR displays a prognostic value for proteinuria [32, 33], 
mortality and RRT [34]. Nevertheless, recent evidence 
indicates NLR was not an independent predictor of 
CKD progression in CKD stage 2–4 patients [35]. In our 
study of a large chinese CKD population for relationship 
between NLR, ESRD, CVD, or all-cause mortality, our 
longitudinal study revealed NLR as an independent risk 
factor of ESRD only in patients with stage 4 CKD after 
adjusting for classic risk factors of CKD including ACR 
and eGFR. These patients have severely damaged renal 
function prior to dialysis [36]; chronic low-grade inflam-
mation will likely promote disease progression towards 
ESRD in stage 4 CKD patients. In this regard, NLR may 
not be an independent predictor of CKD progression in 
patients with CKD at early stages [35]. In renal replace-
ment patients, including hemodialysis and peritoneal 
dialysis, evidence suggests that NLR predicts CVD and 
all-cause mortality [7]. Nevertheless, in our study, this 
relationship could not be demonstrated in pre-dialysis 
patients. It remains possible that NLR predicts CVD and 
all-cause mortality only in stage 5 CKD patients.
Our study has several limitations. First, although most 
well-established risk factors of CKD progression were 
included in our multivariable regression models, the 
possibility of residual confounding still exists. Secondly, 
despite using a large patient cohort organized by multi-
ple centers, risk factor exposures, CVD risk and deaths 
in some regions were affected by data shortages. Thirdly, 
the NLR only captured in 938 of 3358 patients, selection 
bias could not be excluded. Forthly, the cohort has a rela-
tively short duration of follow-up and a limited number 
of cardiovascular events and death [37], which limited 
our power to investigate the association between the lev-
els of NLR and CVD and all-cause mortality.
Conclusion
NLR may independently predict the risk of ESRD in 
patients with stage 4 CKD. NLR is easily available, which 
adds valuable prognostic information to the well-estab-
lished clinical and biochemical prognostic biomark-
ers. NLR could be used to improve risk-stratification of 
patients with stage 4 CKD. Future studies are warranted 
to see whether stage 4 CKD patients with elevated NLR 
levels will benefit from anti-inflammatory therapies and 
interventions.
Additional file
Additional file 1: Table S1. Baseline demographic characteristics of 
participants of C‑STRIDE Study between population with NLR and without 
NLR. Table S2. Relationship between hsCRP and ESRD, CVD and all‑cause 
mortality events rates.
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Fig. 2 Kaplan–Meier curve for ESRD events according to binary of 
NLR
Table 3 Association of NLR with ESRD events among total 
CKD patients and stratified by stage of CKD
Model 1: Adjusted for age, gender
Model 2: Model 1 + smoking, drinking, diabetes, hypertension, cardiovascular 
diseases, hyperuricemia, urine albumin/creatinine ratio, chronic kidney disease-
mineral and bone disorder, hemoglobin, hyperlipidaemia, eGFR
NLR ratio Model 1 Model 2
HR (95% CI) HR (95% CI) 
Total CKD patients (n = 938)
 <  2.09 1.00 (Ref ) 1.00 (Ref ) 
 ≥ 2.09 2.59 (1.72, 3.90) 1.16 (0.74, 1.81)
 p for trend < 0.001 0.512
eGFR ≥ 60 mL/min (n = 360)
 < 2.09 1.00 (Ref ) 1.00 (Ref ) 
 ≥ 2.09 1.77 (0.36, 8.87) 1.57 (0.21, 11.98)
 p for trend 0.485 0.663
30 ≤ eGFR < 60 mL/min (n = 345)
 < 2.09 1.00 (Ref ) 1.00 (Ref ) 
 ≥ 2.09 0.98 (0.50, 1.92) 0.507 (0.23, 1.11)
 p for trend 0.95 0.089
15 ≤ eGFR < 30 mL/min (n = 233)
 < 2.09 1.00 (Ref ) 1.00 (Ref ) 
 ≥ 2.09 2.11 (1.18, 3.76) 2.124 (1.10, 4.10)
 p for trend 0.012 0.025
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